Pfizer Inc. said a new version of its bestselling Prevnar vaccine may provide infants with better protection against common ...
Pfizer Inc. today announced data from its Phase 2 study (NCT06524414) evaluating the safety, tolerability and immunogenicity of a four-dose series of its investigational 25-valent pneumococcal ...
Pfizer Inc. PFE on Wednesday reported positive Phase 2 data for its investigational 25-valent pneumococcal conjugate vaccine ...
The acute myocardial infarction market is experiencing steady growth driven by rising global cardiovascular disease ...
The acute myocardial infarction market is experiencing steady growth driven by rising global cardiovascular disease prevalence and expanding geriatric populations. Advances in diagnostic technologies ...
New data show breakthrough bleeds and surgery were successfully managed for people with hemophilia taking Hympavzi in a large ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results